RE:RE:RE:RE:RE:RE:RE:RE:RE:Get ready for more merger mania in the pharma sector "Existing share price, whatever it is, does not figure into the cost-benefit analysis as it is neither cost nor benefit. It's only a reflection of public sentiment in the moment." - "share prices cannot be realistically relied upon to calculate the actual company value" - Exactly !
The value of a mid-to late stage biotech company like ONCY is in pelareorep's increasing value based on a combination of dynamic factors that include the growing number of indications that the product can be potentially be utilized in, as well as the multiple number of different I/O agents and biologics, such as PD-(L)1 checkpoint inhibitors, CAR-T therapy, bispecifics, small molecules, and PARP, CDK4/6, CD47 inhibitors, for example, that pelareorep can be potentially combined with in multiple further indications, thus making ONCY's pelareorep far different from a mining or oil/gas asset.